Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06533761 is registered in ClinicalTrials.gov with Stelexis BioSciences as lead sponsor.

NCT NCT06533761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06533761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-Label Study to Evaluate the Safety and Tolerability of Eganelisib as Monotherapy and in Combination With Cytarabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
Stelexis BioSciences
Phase
Phase 1
Overall status
Recruiting
Start date
April 28, 2025
Completion date
March 15, 2028
Enrollment
125 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

aml, adult, mds